June Sherie Almenoff
CIK 1492647 · COO and Chief Medical Officer · last filed 2026-09-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FURX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1500 LIBERTY RIDGE DRIVE, SUITE 321
WAYNE, PA 19087
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATNM | Director | 18,000 | $1.40 | $25.2K | $0 | 3 | 2026-09-04 |
| TENX | Director | 3,986 | $1.64 | $6.5K | $29.9K | 7 | 2026-01-13 |
| AVTX | Director | 4,167 | $6.77 | $28.2K | $12.7K | 14 | 2025-06-18 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Director | 878 | $0.75 | $657 | $25.0K | 6 | 2021-12-17 |
| 9 METERS BIOPHARMA, INC. (INNT) Delisted | COO and Chief Medical Officer | 1,400 | — | — | $6.9K | 1 | 2018-08-28 |
| NeuBase Therapeutics, Inc. (OHRP) Delisted | Director | 16,900 | — | — | $58.3K | 5 | 2017-10-18 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | President | 139,713 | — | — | -$13.15M | 10 | 2014-02-06 |
Recent Filings · Page 4 of 5
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-16 | BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted | Grant (A) | +5,700 | $19.9K | EDGAR |
| 2017-10-18 | NeuBase Therapeutics, Inc. (OHRP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-01-11 | NeuBase Therapeutics, Inc. (OHRP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-03-12 | NeuBase Therapeutics, Inc. (OHRP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-02-10 | NeuBase Therapeutics, Inc. (OHRP) Delisted | Buy (P) | +6,000 | $40.5K | EDGAR |
| 2014-09-04 | NeuBase Therapeutics, Inc. (OHRP) Delisted | Buy (P) | +2,200 | $17.8K | EDGAR |
| 2014-07-07 | — | Disp (D) | −24,600 | $0 | |
| 2014-02-06 | Furiex Pharmaceuticals, Inc. (FURX) Delisted | Mixed | — | -$11.90M | EDGAR |
| 2013-06-12 | Furiex Pharmaceuticals, Inc. (FURX) Delisted | Grant (A) | +17,600 | $0 | EDGAR |
| 2012-08-16 | Furiex Pharmaceuticals, Inc. (FURX) Delisted | Buy (P) | +1,000 | $18.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.